Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDED AND RESTATED...Development and Option Agreement • May 28th, 2021 • Verve Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Development and Option Agreement (this “Agreement”), dated as of October 5, 2020 (the “Amendment Effective Date”), is made by and between Verve Therapeutics, Inc. a Delaware corporation (“Verve”) and Acuitas Therapeutics Inc., a British Columbia corporation (“Acuitas”). Each of Verve and Acuitas may be referred to herein as a “Party” or together as the “Parties.”
SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THE REDACTED MATERIAL HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE...Development and Option Agreement • January 7th, 2019 • Alector, Inc. • Biological products, (no disgnostic substances) • Delaware
This Co-Development and Option Agreement (this “Agreement”) is made and entered into effective as of October 16, 2017 (the “Execution Date”) by and between Alector, Inc. (f/k/a Alector LLC), a Delaware corporation (“Licensor”), and AbbVie Biotechnology, Ltd., a Bermuda limited company (“AbbVie”). Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • March 23rd, 2018 • Surface Oncology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS DEVELOPMENT AND OPTION AGREEMENT (the “Agreement”) is made effective as of July 3, 2014 (the “Effective Date”), by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”), and Surface Oncology, Inc., a Delaware corporation having an address at 25 First Street, Suite 303, Cambridge, MA 02141 (“Surface”).
Development and Option Agreement by and between CureVac AG and Arcturus Therapeutics Inc. DatedDevelopment and Option Agreement • June 22nd, 2020 • CureVac B.V. • Pharmaceutical preparations • New York
This Development and Option Agreement (this "Agreement"), dated as of 1 January 2018 (the "Effective Date"), is made by and between CureVac AG, a German stock corporation with offices at Paul-Ehrlich-Strasse 15, 72076 Tübingen, Germany ("CureVac"), and Arcturus Therapeutics Inc., a Delaware corporation with offices at 10628 Science Center Drive # 200, San Diego, CA 92121, USA ("Arcturus"). Each of CureVac and Arcturus may be referred to herein as a "Party" or together as the "Parties".
Development and Option Agreement by and between ACUITAS THERAPEUTICS, INC. and OMEGA THERAPEUTICS, INC. dated October 5, 2020Development and Option Agreement • July 26th, 2021 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS DEVELOPMENT AND OPTION AGREEMENT (this “Agreement”), dated as of October 5, 2020 (the “Effective Date”), is made by and between Omega Therapeutics, Inc. a Delaware corporation (“Omega”) and Acuitas Therapeutics Inc., a British Columbia corporation (“Acuitas”). Each of Omega and Acuitas may be referred to herein as a “Party” or together as the “Parties.”
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed.Development and Option Agreement • June 22nd, 2020 • CureVac B.V. • Pharmaceutical preparations • New York
THIS THIRD AMENDMENT (this “Third Amendment”) to the Development and Option Agreement dated January 1, 2018 (the “Original Agreement”), is entered into by and between CureVac AG, a German stock corporation with offices at Paul-Ehrlich-Strasse 15, 72076 Tubingen, Germany (“CureVac”), and Arcturus Therapeutics Inc., a Delaware corporation with offices at 10628 Science Center Drive #200, San Diego, CA 92121, USA (“Arcturus”; each of CureVac and Arcturus individually a “Party” and together the “Parties”) as of July 26, 2019 (the “Third Amendment Date”).
EXECUTION COPY SIDE AGREEMENT AND AMENDMENT NUMBER ONE to the DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • July 31st, 2020 • CureVac B.V. • Pharmaceutical preparations
THIS SIDE AGREEMENT AND AMENDMENT (“Amendment Agreement”) to the DEVELOPMENT AND OPTION AGREEMENT is entered into effective as of December 1, 2016 (the “Amendment One Date”), by and between ACUITAS THERAPEUTICS INC., with offices at 2714 West 31st Avenue, Vancouver, British Columbia, V6L 2Al, Canada (“Acuitas”), and CUREVAC AG, a company incorporated in Germany whose registered office is at Paul-Ehrlich-Straf3e 15, 72076 Tübingen, Germany (“CureVac”).
FIRST AMENDMENT TO THEDevelopment and Option Agreement • August 5th, 2020 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances)
This First Amendment (the “First Amendment”) to the Development and Option Agreement dated November 20, 2019 (the “Agreement”) by and between Harpoon Therapeutics, Inc., a Delaware corporation (“Harpoon”), and AbbVie Biotechnology Ltd, a Bermuda corporation (“AbbVie”) is made effective as of the date of the final signature to this First Amendment. Harpoon and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
DEVELOPMENT AND OPTION AGREEMENT Dated as of December 22, 2011 by and between VIROPHARMA INCORPORATED and MERITAGE PHARMA, INC.Development and Option Agreement • February 28th, 2012 • Viropharma Inc • Pharmaceutical preparations • Delaware
THIS DEVELOPMENT AND OPTION AGREEMENT (this “Agreement”) is made and entered into as of December 22, 2011 by and between ViroPharma Incorporated, a Delaware corporation (“Optionee”), and Meritage Pharma, Inc., a Delaware corporation (the “Company”).
AMENDMENT NO. 1 TO CO-DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • May 4th, 2023 • Alector, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 (this “Amendment”) is effective as of February 13, 2023 (the “Amendment Effective Date”) by and between Alector, Inc., a Delaware corporation (“Licensor”), and AbbVie Biotechnology Ltd. (“AbbVie”). Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 1 - DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • May 8th, 2014 • Zogenix, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 – DEVELOPMENT AND OPTION AGREEMENT (the “Amendment No. 1”) is made as of March 10th, 2014 (the “Amendment No. 1 Effective Date”), by and between ALTUS FORMULATION INC., a Quebec company, having its principal place of business at 17800 Rue Lapointe, Mirabel Quebec J7J 1P3, Canada (“Altus”), and ZOGENIX, INC., a Delaware corporation, having its principal place of business at 12400 High Bluff Drive, Suite 650, San Diego, CA 92130 USA (“Zogenix”). Each of Altus and Zogenix are sometimes referred to herein individually as a “Party” and together as the “Parties”.
FIRST AMENDED AND RESTATED DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • November 13th, 2018 • Surface Oncology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This First Amended and Restated Development and Option Agreement (this “Agreement”) made effective as of October 3, 2018 (the “Amended Effective Date”), is entered into by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”), and Surface Oncology, Inc., a Delaware corporation having an address at 25 First Street, Suite 303, Cambridge, MA 02141 (“Surface”).
DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • August 12th, 2010 • Quick-Med Technologies Inc • Surgical & medical instruments & apparatus • Florida
This Development and Option Agreement (“Agreement”) is entered into as of August 6, 2010 (“Effective Date”) by and between Biosara Corporation, a Delaware corporation, with a principal place of business in Corinth, Texas (“Biosara”) and Quick-Med Technologies, Inc., a Nevada corporation, having its principal office at 902 NW 4th Street, Gainesville, Florida 32601 (hereinafter referred to as “Quick-Med”).
DEVELOPMENT AND OPTION AGREEMENT Dated as of December 22, 2011 by and between VIROPHARMA INCORPORATED and MERITAGE PHARMA, INC.Development and Option Agreement • August 2nd, 2012 • Viropharma Inc • Pharmaceutical preparations • Delaware
THIS DEVELOPMENT AND OPTION AGREEMENT (this “Agreement”) is made and entered into as of December 22, 2011 by and between ViroPharma Incorporated, a Delaware corporation (“Optionee”), and Meritage Pharma, Inc., a Delaware corporation (the “Company”).
FIRST AMENDED AND RESTATED DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • March 15th, 2024 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This First Amended and Restated Development and Option Agreement (this “Agreement”) made effective as of October 3, 2018 (the “Amended Effective Date”), is entered into by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”), and Surface Oncology, Inc., a Delaware corporation having an address at 25 First Street, Suite 303, Cambridge, MA 02141 (“Surface”).
AMENDMENT NO. 3 - DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • March 11th, 2015 • Zogenix, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 3 – DEVELOPMENT AND OPTION AGREEMENT (the “Amendment No. 3”) is made as of October 30, 2014 (the “Amendment No. 3 Effective Date”), by and between ALTUS FORMULATION INC., a Quebec company, having its principal place of business at 17800 Rue Lapointe, Mirabel Quebec J7J 1P3, Canada (“Altus”), and ZOGENIX, INC., a Delaware corporation, having its principal place of business at 12400 High Bluff Drive, Suite 650, San Diego, CA 92130 USA (“Zogenix”). Each of Altus and Zogenix are sometimes referred to herein individually as a “Party” and together as the “Parties”.
RESTATED AMENDMENT TO DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • June 22nd, 2020 • CureVac B.V. • Pharmaceutical preparations • New York
THIS RESTATED AMENDMENT TO DEVELOPMENT AND OPTION AGREEMENT (this “Amendment”), dated as of September 28, 2018 (the “Amendment Restatement Date”), is made by and between CureVac AG, a German stock corporation with offices at Paul-Ehrlich-Strasse 15, 72076 Tubingen, Germany (“CureVac”), and Arcturus Therapeutics Inc., a Delaware corporation with offices at 10628 Science Center Drive #200, San Diego, CA 92121, USA (“Arcturus”). Each of CureVac and Arcturus may be referred to herein as a “Party” or together as the “Parties”.
DEVELOPMENT AND OPTION AGREEMENT betweenDevelopment and Option Agreement • March 12th, 2020 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Development and Option Agreement (the “Agreement”) is made and entered into effective as of November 20, 2019 (the “Effective Date”) by and between Harpoon Therapeutics, Inc., a Delaware corporation (“Harpoon”), and AbbVie Biotechnology Ltd, a Bermuda corporation (“AbbVie”). Harpoon and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • March 7th, 2014 • Zogenix, Inc. • Pharmaceutical preparations • New York
THIS DEVELOPMENT AND OPTION AGREEMENT (this “Agreement”) is made as of November 1, 2013 (the “Effective Date”), by and between ALTUS FORMULATION INC., a Quebec company having its principal place of business at 17800 Rue Lapointe, Mirabel Quebec J7J 1P3, Canada (“Altus”), and ZOGENIX, INC., a Delaware corporation having its principal place of business at 12400 High Bluff Drive, Suite 650, San Diego, CA 92130 USA (“Zogenix”). Each of Altus and Zogenix are sometimes referred to herein individually as a “Party” and together as the “Parties”.
Development and Option Agreement by and between ACUITAS THERAPEUTICS, INC. and GREENLIGHT BIOSCIENCES INC. dated August 24, 2020Development and Option Agreement • October 19th, 2021 • Environmental Impact Acquisition Corp • Biological products, (no disgnostic substances) • New York
This Development and Option Agreement (this “Agreement”), dated as of August 24, 2020 (the “Effective Date”), is made by and between GreenLight Biosciences Inc., a Delaware corporation, (“GreenLight”) and Acuitas Therapeutics Inc., a British Columbia corporation (“Acuitas”). Each of GreenLight and Acuitas may be referred to herein as a “Party” or together as the “Parties.”
AMENDMENT NO. 2 - DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • November 6th, 2014 • Zogenix, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 2 – DEVELOPMENT AND OPTION AGREEMENT (the “Amendment No. 2”) is made as of September 15th, 2014 (the “Amendment No. 2 Effective Date”), by and between ALTUS FORMULATION INC., a Quebec company, having its principal place of business at 17800 Rue Lapointe, Mirabel Quebec J7J 1P3, Canada (“Altus”), and ZOGENIX, INC., a Delaware corporation, having its principal place of business at 12400 High Bluff Drive, Suite 650, San Diego, CA 92130 USA (“Zogenix”). Each of Altus and Zogenix are sometimes referred to herein individually as a “Party” and together as the “Parties”.
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. Amendment Two to Development and Option AgreementDevelopment and Option Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations
This Amendment Two to the Development and Option Agreement (this "Amendment"), dated as of July 10, 2020 (the "Amendment Two Effective Date"), is made by and between CureVac AG, a German stock corporation with offices at Friedrich-Miescher-Strasse 15, 72076 Tubingen, Germany ("CureVac"), and Acuitas Therapeutics Inc., a British Columbia corporation ("Acuitas") and amends and restates the Development and Option Agreement dated April 29, 2016 (as amended by the Side Agreement and Amendment Number One dated December 1,2016) between CureVac and Acuitas (the "Development and Option Agreement"). Each of CureVac and Acuitas may be referred to herein as a "Party" or together as the "Parties."
Amendment Four to Development and Option AgreementDevelopment and Option Agreement • April 25th, 2024 • CureVac N.V. • Pharmaceutical preparations
This Amendment Four to the Development and Option Agreement (this "Amendment"), dated as of February 13, 2024 (the "Amendment Four Effective Date"), is made by and between CureVac SE, a German stock corporation with offices at Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany ("CureVac"), and Acuitas Therapeutics Inc., a British Columbia corporation with offices at 6190 Agronomy Road, Suite 405, Vancouver, British Columbia, V6T 1Z3, Canada ("Acuitas") and amends the Development and Option Agreement dated April 29, 2016, as amended by Side Agreement and Amendment Number One dated December 1, 2016, Amendment Two to the Development and Option Agreement dated July 10, 2020, and Amendment Three dated December 24, 2020 by and between CureVac and Acuitas (collectively as amended, the “D&O Agreement”).
EXHIBIT 10(y) DEVELOPMENT AND OPTION AGREEMENT This Agreement, dated as of August 27, 1996, is by and between Misonix Incorporated, a New York corporation, with its principal place of business at 1928 New Highway, Farmingdale, New York 11735...Development and Option Agreement • September 24th, 1997 • Misonix Inc • Laboratory apparatus & furniture • New York
CERTAIN CONFIDENTIAL INFORMATION IDENTIFIED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Private and Confidential Dated April...Development and Option Agreement • August 17th, 2020 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS DEVELOPMENT AND OPTION AGREEMENT (this “Agreement”), effective as of April 21, 2020 (the “Effective Date”), is entered into by and between NAVITOR PHARMACEUTICALS, INC., a company registered under the laws of the state of Delaware having offices at 1030 Massachusetts Avenue, Suite 410, Cambridge, MA 02138 (“Navitor”) and SUPERNUS PHARMACEUTICALS, INC., a corporation registered under the laws of the state of Delaware having offices at 9715 Key West Avenue, Rockville, MD 20850 (“Supernus”).
Amendment Three to Development and Option AgreementDevelopment and Option Agreement • January 25th, 2021 • CureVac N.V. • Pharmaceutical preparations
This Amendment Three to the Development and Option Agreement (this "Amendment"), dated as of December 24, 2020 (the "Amendment Three Effective Date"), is made by and between CureVac AG, a German stock corporation with offices at Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany ("CureVac"), and Acuitas Therapeutics Inc., a British Columbia corporation with offices at 6190 Agronomy Road, Suite 405, Vancouver, British Columbia, V6T 1Z3, Canada ("Acuitas") and amends the Development and Option Agreement dated April 29, 2016 (as amended by Side Agreement and Amendment Number One dated December 1, 2016 and Amendment Two to the Development and Option Agreement dated July 10, 2020) between CureVac and Acuitas (as amended, the “Development and Option Agreement”). Each of CureVac and Acuitas may be referred to herein as a "Party" or together as the "Parties."
DEVELOPMENT AND OPTION AGREEMENT BETWEEN SCHERING CORPORATION AND CIMA LABS, INC.Development and Option Agreement • November 14th, 1997 • Cima Labs Inc • Pharmaceutical preparations • New Jersey
CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option AgreementDevelopment and Option Agreement • February 19th, 2019
ZUG, Switzerland and CAMBRIDGE, Mass. and Durham, N.C., Feb. 19, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV)-based gene therapies, today announced that a strategic collaboration, previously initiated in April 2017 to generate engineered AAV capsids with improved properties for in vivo gene editing programs, has now been expanded to include additional undisclosed applications. The financial terms of the new expanded development and option agreement have not been disclosed.
RESTATED AMENDMENT TO DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • October 1st, 2018 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations • New York
THIS RESTATED AMENDMENT TO DEVELOPMENT AND OPTION AGREEMENT (this “Amendment”), dated as of September 28, 2018 (the “Amendment Restatement Date”), is made by and between CureVac AG, a German stock corporation with offices at Paul-Ehrlich-Strasse 15, 72076 Tubingen, Germany (“CureVac”), and Arcturus Therapeutics Inc., a Delaware corporation with offices at 10628 Science Center Drive #200, San Diego, CA 92121, USA (“Arcturus”). Each of CureVac and Arcturus may be referred to herein as a “Party” or together as the “Parties”.
